The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
Go-ahead for pivotal clinical trial which is expected to commence by March
An article by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of the Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, has been published in medRxiv
The drug is to be supplied in 105 low and middle-income countries and 10 Indian firms are on the list
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Biocon has reported consolidated financial results for the period ended December 31, 2021
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Bio-catalysis and Electro-catalysis emerge as most preferred green chemistry technologies
CliniSys has the proven ability to deliver 100s of millions of medical results a month to enable pandemic-scale population disease surveillance across the globe
This is the company’s first partnership arrangement in China
Subscribe To Our Newsletter & Stay Updated
